Drug intelligence / Profile preview

Safetussin

Development stage
Unknown
Lead developer
Kramer Laboratories
Modality
Small Molecules
Administration
Oral
01

Overview

**Safetussin** is a United States over-the-counter cough, cold, and flu product brand rather than one chemically uniform drug. Its marketed formulations are fixed-dose oral small-molecule combinations designed for temporary symptomatic relief and positioned for adults with high blood pressure or diabetes. Safetussin DM contains dextromethorphan, a centrally acting cough suppressant, plus guaifenesin, an expectorant that helps loosen respiratory mucus; Safetussin PM contains dextromethorphan plus the sedating H1 antihistamine doxylamine; and Safetussin Multi-Symptom products contain acetaminophen, dextromethorphan, and guaifenesin. Historical Safetussin CD products contained dextromethorphan plus phenylephrine. Because the unqualified brand name covers multiple formulations with distinct active ingredients, it should not be treated as one unique molecular entity. ([safetussin.com](https://safetussin.com/products/))

Brand names
SafetussinSafetussin CDSafetussin DMSafetussin Max Strength Multi-Symptom Cough, Cold & FluSafetussin MS Cough, Cold & FluSafetussin PM
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRA1A (α1A)

Beyond the preview

Go deeper on Safetussin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Safetussin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call